Roberto Henrique Nussenzveig

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8431742/publications.pdf

Version: 2024-02-01

21 papers 589

933447 10 h-index 752698 20 g-index

21 all docs

21 docs citations

21 times ranked

941 citing authors

#	Article	IF	CITATIONS
1	Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends in Cancer, 2020, 6, 702-715.	7.4	122
2	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer, 2018, 124, 2115-2124.	4.1	79
3	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. , 2020, 8, e001065.		70
4	Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. European Urology, 2020, 78, 652-656.	1.9	64
5	Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. Annals of Translational Medicine, 2019, 7, S18-S18.	1.7	44
6	Circulating tumor DNA alterations in patients with metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 1459-1469.	4.1	38
7	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. Oncologist, 2021, 26, e270-e278.	3.7	33
8	Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, 288-292.	1.9	23
9	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. Cancers, 2021, 13, 4951.	3.7	19
10	Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 2104-2110.	7.0	15
11	Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist, 2021, 26, 1006-e2129.	3.7	13
12	Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. Oncologist, 2018, 23, 1413-e151.	3.7	11
13	Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. Drugs, 2021, 81, 191-206.	10.9	11
14	Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. Cancer Treatment and Research Communications, 2019, 19, 100120.	1.7	10
15	Germline Variant in <i>SLCO2B1</i> and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). Molecular Cancer Therapeutics, 2019, 18, 726-729.	4.1	9
16	Identification of Somatic Gene Signatures in Circulating <scp>Cell-Free DNA</scp> Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. Oncologist, 2021, 26, 751-760.	3.7	9
17	Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e169-e172.	1.9	7
18	Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma. Journal of Urology, 2021, 205, 709-717.	0.4	7

ROBERTO HENRIQUE

#	Article	IF	CITATIONS
19	Germline variants and response to systemic therapy in advanced prostate cancer. Pharmacogenomics, 2020, 21, 75-81.	1.3	2
20	Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treatment and Research Communications, 2020, 24, 100193.	1.7	2
21	Quest for Ideal Composite Biomarkers for Response to Immunotherapies. Clinical Cancer Research, 2020, 26, 5059-5061.	7.0	1